Furthermore, Shi et al. noted that lymph node metastasis, tumor diameter, and Ki67 expression were risk factors affecting the 5 year DFS rates in patients with ultra-low HER2 expression [21]. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.